NR1H4 and metabolic dysfunction-associated steatohepatitis: As such, future studies will determine the efficacy of P2RX7 inhibitors in NASH patients, both as a stand-alone treatment and in concert with agents targeting pathways that affect other pathological aspects of NASH such as obeticholic acid (Farnesoid X receptor agonist), pioglitazone (peroxisome proliferator-activated receptor (PPAR)-γ agonist) and elafibranor (PPAR-α/δ agonist).